{"entity":{"id":"nct04064060","kind":"trial","name":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","aka":[],"tldr":"A phase 3 trial of Luspatercept in myelodysplastic syndromes / neoplasms and myeloproliferative neoplasms, run by Celgene, now recruiting.","summary":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials is a phase 3 interventional study registered as NCT04064060 by Celgene, with 665 participants planned, started 2019-08-12 and due to reach its primary completion in 2028-05-12. Interventions recorded: Luspatercept.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04064060","url":"https://clinicaltrials.gov/study/NCT04064060"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mds","myeloproliferative-neoplasms"],"sections":[],"technologies":["transfusion-support"],"targets":[],"drugs":["luspatercept"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04064060","phase":"3","setting":"A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","sponsor":"Celgene","participation":[{"nct":"NCT04064060","source":"https://clinicaltrials.gov/study/NCT04064060","fetchedAt":"2026-10-07T16:53:13.478Z","studySha256":"5d81a51bc53e6fdf92f47d38e2f2064581686b7c6342c8098370ceda1e4d1ada","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-01","leadSponsor":"Celgene","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":665,"enrolmentType":"ESTIMATED","siteCount":143,"recruitingSiteCount":27,"countries":["Australia","Belgium","Bulgaria","Canada","China","France","Germany","Greece","Israel","Italy","Japan","Lebanon","Malaysia","Netherlands","Spain","Sweden","Taiwan","Thailand","Tunisia","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2019-08-12","startedType":"actual","enrolled":665,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04064060/","neighbours":{"cancer":[{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"technology":[{"id":"transfusion-support","kind":"technology","name":"Transfusion support and anaemia management","route":"/technologies/transfusion-support/"}],"drug":[{"id":"luspatercept","kind":"drug","name":"Luspatercept","route":"/drugs/luspatercept/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}